Clinical Trials Directory

Trials / Terminated

TerminatedNCT02433067

Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer

Impact of Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer, During Treatment With Trastuzumab in Adjuvant

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
89 (actual)
Sponsor
University of Franche-Comté · Academic / Other
Sex
Female
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Purpose of the study is to examine the effects of 3 months of physical activity intervention on myocardial function (Left ventricular ejection fraction) in patients with HER2+ breast cancer

Detailed description

Primary objective: To evaluate in patients with HER2 + breast cancer, treated only by trastuzumab, the impact of three months individualized physical activity intervention (55 minutes, 3 times per week) on left ventricular ejection fraction (LVEF). Secondary objectives: To evaluate the impact of physical activity intervention on body composition, muscle function, metabolic, hormonal and inflammatory responses, pain, fatigue and quality of life. This study examines patients aged 18 to 85 years, diagnosed with early breast cancer with HER2 overexpression confirmed histologically and eligible to receive treatment with trastuzumab (adjuvant). This study includes 3 assessments phases: baseline (T0), 3 months (T3) and 6 months (T6) for both arms. The programme is organised as follows: Arm A "standard oncologic care coupled with physical activity intervention (3 times / week) " for 3 months ; Arm B (control group) "standard oncologic care". Between T3 and T6, volontary physical activity level will follow by actimetry.

Conditions

Interventions

TypeNameDescription
OTHERPhysical activity interventionPatients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
OTHERControl Groupstandard oncologic care

Timeline

Start date
2015-04-01
Primary completion
2020-10-01
Completion
2020-10-01
First posted
2015-05-04
Last updated
2020-10-06

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02433067. Inclusion in this directory is not an endorsement.